Cargando…
Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study
AIM: To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). METHODS: This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Croatian Medical Schools
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045893/ https://www.ncbi.nlm.nih.gov/pubmed/29972735 http://dx.doi.org/10.3325/cmj.2018.59.124 |
_version_ | 1783339747314237440 |
---|---|
author | Glamočlija, Una Tubić, Biljana Kondža, Martin Zolak, Aleksandar Grubiša, Nataša |
author_facet | Glamočlija, Una Tubić, Biljana Kondža, Martin Zolak, Aleksandar Grubiša, Nataša |
author_sort | Glamočlija, Una |
collection | PubMed |
description | AIM: To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). METHODS: This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&H in 2011-2016. The number, characteristics, and sources of reports, suspected drugs, and patient characteristics were analyzed. The results were compared with the publicly available data from Croatia, Serbia, and Montenegro. RESULTS: The number of reported adverse drug reactions per one million of inhabitants was lowest in B&H and highest in Croatia. There were significant differences in reporter characteristics, sources of reports, and the percentage of missing data in ICSR, while the Anatomical Therapeutic Chemical product classes, patient’s sex, and adverse drug reaction System Organ Classes were similar. CONCLUSION: Despite the historical and geographical vicinity of B&H and its neighboring countries, there were significant differences in indicators of pharmacovigilance development. |
format | Online Article Text |
id | pubmed-6045893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Croatian Medical Schools |
record_format | MEDLINE/PubMed |
spelling | pubmed-60458932018-07-18 Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study Glamočlija, Una Tubić, Biljana Kondža, Martin Zolak, Aleksandar Grubiša, Nataša Croat Med J Pharmacoepidemiology AIM: To compare individual case safety reports (ICSR) rates and characteristics between Croatia, Serbia, Montenegro, and Bosnia and Herzegovina (B&H). METHODS: This retrospective pharmacoepidemiological study used the data from ICSR received by the Agency for Medicines and Medical Devices in B&H in 2011-2016. The number, characteristics, and sources of reports, suspected drugs, and patient characteristics were analyzed. The results were compared with the publicly available data from Croatia, Serbia, and Montenegro. RESULTS: The number of reported adverse drug reactions per one million of inhabitants was lowest in B&H and highest in Croatia. There were significant differences in reporter characteristics, sources of reports, and the percentage of missing data in ICSR, while the Anatomical Therapeutic Chemical product classes, patient’s sex, and adverse drug reaction System Organ Classes were similar. CONCLUSION: Despite the historical and geographical vicinity of B&H and its neighboring countries, there were significant differences in indicators of pharmacovigilance development. Croatian Medical Schools 2018-06 /pmc/articles/PMC6045893/ /pubmed/29972735 http://dx.doi.org/10.3325/cmj.2018.59.124 Text en Copyright © 2018 by the Croatian Medical Journal. All rights reserved. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Pharmacoepidemiology Glamočlija, Una Tubić, Biljana Kondža, Martin Zolak, Aleksandar Grubiša, Nataša Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study |
title | Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study |
title_full | Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study |
title_fullStr | Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study |
title_full_unstemmed | Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study |
title_short | Adverse drug reaction reporting and development of pharmacovigilance systems in Bosnia and Herzegovina, Croatia, Serbia, and Montenegro: a retrospective pharmacoepidemiological study |
title_sort | adverse drug reaction reporting and development of pharmacovigilance systems in bosnia and herzegovina, croatia, serbia, and montenegro: a retrospective pharmacoepidemiological study |
topic | Pharmacoepidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045893/ https://www.ncbi.nlm.nih.gov/pubmed/29972735 http://dx.doi.org/10.3325/cmj.2018.59.124 |
work_keys_str_mv | AT glamoclijauna adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy AT tubicbiljana adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy AT kondzamartin adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy AT zolakaleksandar adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy AT grubisanatasa adversedrugreactionreportinganddevelopmentofpharmacovigilancesystemsinbosniaandherzegovinacroatiaserbiaandmontenegroaretrospectivepharmacoepidemiologicalstudy |